卢旺达耐多药结核分枝杆菌分离株中二线药物耐药水平较低。
Low levels of second-line drug resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Rwanda.
作者信息
Umubyeyi A, Rigouts L, Shamputa I C, Dediste A, Struelens M, Portaels F
机构信息
Department of Microbiology, CHU St Pierre, Brussels, Belgium.
出版信息
Int J Infect Dis. 2008 Mar;12(2):152-6. doi: 10.1016/j.ijid.2007.05.003. Epub 2007 Oct 18.
BACKGROUND
Multidrug-resistant tuberculosis (MDR-TB) has become a therapeutic problem in many parts of the world, necessitating the inclusion of second-line anti-tuberculosis drugs in specific treatment regimens.
METHODS
We studied the susceptibility of 69 MDR Mycobacterium tuberculosis isolates from Rwanda to second-line drugs by the BACTEC 460 method.
RESULTS
The results showed that 62 (89.9%) were resistant to rifabutin while a low rate (4.3%) of resistance was registered for ofloxacin; there was one case (1.4%) of resistance each for para-aminosalicylic acid, kanamycin, ethionamide, and clarithromycin.
CONCLUSIONS
This information is important for devising an appropriate treatment regimen for MDR-TB patients in order to stop the spread of MDR strains and contain the acquisition of additional drug resistance in Rwanda.
背景
耐多药结核病（MDR-TB）已成为世界许多地区的治疗难题，这使得在特定治疗方案中纳入二线抗结核药物成为必要。
方法
我们采用BACTEC 460方法研究了来自卢旺达的69株耐多药结核分枝杆菌分离株对二线药物的敏感性。
结果
结果显示，62株（89.9%）对利福布汀耐药，而氧氟沙星的耐药率较低（4.3%）；对对氨基水杨酸、卡那霉素、乙硫异烟胺和克拉霉素各有1例（1.4%）耐药。
结论
这些信息对于为卢旺达的耐多药结核病患者制定合适的治疗方案非常重要，以便阻止耐多药菌株的传播并遏制额外耐药性的产生。
Zotero 插件